|[January 26, 2013]
Law Office of Brodsky & Smith, LLC Announces Investigation of MAP Pharmaceuticals, Inc.
BALA CYNWYD, Pa. --(Business Wire)--
Law office of Brodsky & Smith, LLC announces that it is investigating
potential claims against the Board of Directors of MAP Pharmaceuticals,
Inc. ("MAP" or the "Company") (Nasdaq: MAPP) relating to the proposed
acquisition by Allergan, Inc. ("Allergan").
Under the terms of the transaction, MAP shareholders will receive only
$25.00 in cash for each share of MAP stock they own. The investigation
concerns possible breaches of fiduciary duty and other violations of
state law by the Board of Directors of MAP for not acting in the
Company's shareholders' best interests in connection with the sale
process to Allergn. MAP is expected to receive a decision on its
inhalable migraine treatment Levadex by the Food and Drug Administration
before mid-April. It has been reported that the global migraine drug
market will reach $5.8 billion by 2021.
If you own shares of MAP stock and wish to discuss the legal
ramifications of the proposed transaction, or have any questions, you
may e-mail or call the law office of Brodsky & Smith, LLC who will,
without obligation or cost to you, attempt to answer your questions. You
may contact Jason L. Brodsky, Esquire or Evan J. Smith, Esquire at
Brodsky & Smith, LLC, Two Bala Plaza, Suite 602, Bala Cynwyd, PA 19004,
by e-mail at email@example.com
by calling toll free 877-LEGAL-90.
[ Back To Technology News's Homepage ]